Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
AbbVie Inc Market Cap
Based on ratings from 29 stock analysts, the AbbVie Inc stock price is expected to increase by 14.59% in 12 months. This is calculated by using the average 12-month stock price forecast for AbbVie Inc. The lowest target is $165 and the highest is $240. Please note analyst price targets are not guaranteed and could be missed completely.
About 29 Wall Street analysts have assignedABBV 19 buy ratings, 10 hold ratings, and 0 sell ratings. This means that analysts expect AbbVie Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ABBV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ABBV.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Risinger Leerink Partners | Outperform | $206 | Upgrade | Nov 22, 2024 |
| Alexandria Hammond Wolfe Research | Outperform | $205 | Initiates | Nov 15, 2024 |
| Chris Schott JP Morgan | Overweight | $200 | Maintains | Nov 13, 2024 |
| Terence Flynn Morgan Stanley | Overweight | $224 | Maintains | Nov 12, 2024 |
| Evan David Seigerman BMO Capital | Outperform | $208 | Maintains | Nov 12, 2024 |
| Geoff Meacham Citigroup | Buy | $215 | Maintains | Nov 12, 2024 |
| Vamil Divan Guggenheim | Buy | $221 | Maintains | Nov 6, 2024 |
| David Toung Argus Research | Buy | Upgrade | Nov 4, 2024 | |
| Terence Flynn Morgan Stanley | Overweight | $231 | Maintains | Oct 31, 2024 |
| Navin Jacob UBS | Neutral | $200 | Maintains | Oct 31, 2024 |
| Geoff Meacham Citigroup | Buy | $226 | Maintains | Oct 31, 2024 |
| Andrew Baum Citigroup | Buy | $215 | Maintains | Oct 25, 2024 |
| Geoff Meacham B of A Securities | Neutral | $195 | Maintains | Oct 18, 2024 |
| Aaron Gal Bernstein | Market Perform | $203 | Initiates | Oct 17, 2024 |
| Evan David Seigerman BMO Capital | Outperform | $220 | Maintains | Oct 17, 2024 |
| Srikripa Devarakonda Truist Securities | Buy | $215 | Maintains | Oct 10, 2024 |
| Navin Jacob UBS | Neutral | $195 | Maintains | Oct 9, 2024 |
| Carter Gould Barclays | Overweight | $212 | Maintains | Oct 7, 2024 |
| Steve Scala TD Cowen | Buy | $225 | Maintains | Oct 7, 2024 |
| Christopher Raymond Piper Sandler | Overweight | $209 | Maintains | Aug 23, 2024 |
When did it IPO
2013
Staff Count
50,000
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - General
CEO
Mr. Robert A. Michael
Market Cap
$312.02B
In 2023, ABBV generated $54.32B in revenue, which was a decrease of -6.44% from the previous year. This can be seen as a signal that ABBV's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Reuters
Summary - AbbVie's experimental Parkinson's drug successfully met its main goal in a late-stage study, indicating potential progress in treatment options.
Why It Matters - AbbVie's successful late-stage trial for a Parkinson's drug may boost its stock value and market position, indicating potential revenue growth and a strong pipeline.
Mon, 09 Dec 2024
Sentiment - POSITIVE
Source - Market Watch
Summary - AbbVie Inc. reported positive results from a late-stage trial for a Parkinson's disease treatment and plans to seek FDA approval in 2025.
Why It Matters - Positive trial results for AbbVie's Parkinson's treatment could lead to FDA approval, potentially boosting the company's market position and stock value in the competitive pharmaceutical sector.
Sat, 07 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - AbbVie presented updated results from its Phase 1b/2 EPCORE® NHL-2 trial for epcoritamab, a bispecific antibody, combined with R2 therapy in adults with relapsed follicular lymphoma.
Why It Matters - Positive trial results for AbbVie's epcoritamab could indicate potential FDA approval and market success, impacting revenue growth and stock performance for the company.
Sun, 08 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - AbbVie released an Emotional Impact Report revealing that Black, Hispanic, and Asian patients with chronic lymphocytic leukemia (CLL) experience more negative emotional effects related to their diagnosis and treatment.
Why It Matters - The emotional impact of CLL on diverse patient groups may influence AbbVie's market position and treatment strategies, potentially affecting sales and stock performance in the oncology sector.
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - AbbVie reported positive results from the Phase 3 TEMPO-2 trial for tavapadon, a potential Parkinson's treatment. The company plans to submit an NDA to the FDA in 2025.
Why It Matters - Positive trial results for tavapadon enhance AbbVie's growth prospects in Parkinson's treatment, potentially leading to FDA approval and increased market share, influencing stock performance.
Mon, 09 Dec 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - AbbVie presented new clinical trial results for epcoritamab, a bispecific antibody for DLBCL, at the ASH annual meeting, potentially impacting its oncology pipeline.
Why It Matters - Positive clinical trial results for AbbVie's epcoritamab could enhance its market position in cancer treatment, potentially boosting revenue and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
